Eyelids play a very important role in protecting our eyes by sweeping away dirt and spreading moisture (tears) over the surface. Eyelid diseases represent one of the largest untapped opportunities in ophthalmology. Among these, blepharitis and meibomian gland dysfunction are very common, and yet, they often go underdiagnosed and underappreciated in clinical practice.
The stock we are bringing to your attention today is that of Tarsus Pharmaceuticals Inc. (TARS), a biopharmaceutical company developing therapeutic candidates for pervasive and damaging eyelid diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com